June 19, 2017 - June 22, 2017
San Diego, CA
Panelist: Roger Longman
Real Endpoints LLC
Value assessment frameworks are a relatively new concept designed to help stakeholders determine what treatments provide the most value in healthcare. They are sometimes influential in determining what therapies are chosen by patients and their doctors, and often used to determine if those therapies will be covered and reimbursed by payers. How these frameworks consider personalized medicine is not yet clear. Designed before 25% of all new drugs were personalized medicines, value frameworks might need to evolve to keep pace with scientific discovery and recognize the leading role of diagnostic testing in targeting therapeutic use. This session will examine how value assessment frameworks have been developed historically, examine the current critiques of their processes and methodologies and explore how they might have to change in the future to support personalized medicine.
view event >June 8, 2020 - June 12, 2020
Moderator: Jeffrey Berkowitz, CEO and Director
Real Endpoints
Real Endpoints is excited to be moderating this important panel on reimbursement of chronic rare and orphan disease therapies at the upcoming BIO International Digital Convention
May 19, 2020 12:00pm ET
Panelist: Jeffrey Berkowitz, CEO and Director
Roger Longman, Founder and Chairman
Real Endpoints
CELLO Health BioConsulting Webinar with Real Endpoints: In this senior executive webinar, we’ll give a boardroom presentation, and take your questions, on cancer’s unique payer situation and its stability — or instability. Our focus: how the informed biotech executive team manages early (and late) clinical and commercial development to ensure success not just with the FDA but in what may be a very different and less favorable reimbursement environment
May 4, 2020 12:30pm ET
HBO show!
Chief Clinical Officer: Jane F. Barlow, MD, MPH, MBA
Real Endpoints
Watch the replay of Real Endpoint’s Jane Barlow – joined by Congressman Scott Peters – speaking to the challenges of seeking reimbursement for cell and gene therapy during a time of upheaval.
October 16, 2019 - October 18, 2019
New York, NY
Speaker: Jeff Berkowitz
Roger Longman
Real Endpoints
Value-based pharma contracts have been rare in oncology relative to other therapeutic categories — and for a variety of good and bad reasons. But in the hyper-competitive future, risk-sharing will become a necessary component in every oncology company’s strategic toolkit. In five separate sessions at the value-based cancer summit in NY Oct 16-18, Real Endpoints CEO Jeff Berkowitz and Chairman Roger Longman will help lay out the challenges and the unexploited opportunities in oncology VBAs
October 13, 2019 - October 15, 2019
Laguna Beach, CA
Jeff Berkowitz
Real Endpoints
Biotech’s CEOs at the annual Laguna meeting next week will be talking — as are their investors — about how to pay for innovation, particularly as the industry runs from major chronic disease to narrow orphan indications where pricing has been relatively protected. Real Endpoints’ CEO Jeff Berkowitz will be on a panel defining the increasing challenges of this approach, particularly given how competitive even the narrowest orphan conditions have become, and how companies must adapt to meet them.
October 2, 2019 1:15pm
San Diego, CA
Roger Longman
Real Endpoints
Real Endpoints Founder, Roger Longman, is looking forward to leading a robust discussion focused on solutions to creating access to cell and gene therapies — solutions that work for both payers and biopharma.
Manager
Payer & Channel Insights, Marketing Analytics & Business Insights